Wall Street analysts expect that Pfizer Inc. (NYSE:PFE) will report earnings per share (EPS) of $0.64 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Pfizer’s earnings, with the lowest EPS estimate coming in at $0.63 and the highest estimate coming in at $0.66. Pfizer reported earnings per share of $0.62 in the same quarter last year, which suggests a positive year-over-year growth rate of 3.2%. The company is scheduled to announce its next earnings results before the market opens on Tuesday, January 29th.

According to Zacks, analysts expect that Pfizer will report full year earnings of $3.00 per share for the current financial year, with EPS estimates ranging from $2.98 to $3.02. For the next financial year, analysts expect that the business will report earnings of $3.07 per share, with EPS estimates ranging from $2.95 to $3.15. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Pfizer.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The business had revenue of $13.30 billion during the quarter, compared to analyst estimates of $13.53 billion. During the same quarter last year, the company posted $0.67 EPS. Pfizer’s revenue for the quarter was up 1.0% on a year-over-year basis.

A number of equities analysts recently weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research report on Wednesday, October 17th. Credit Suisse Group set a $45.00 price target on shares of Pfizer and gave the company a “hold” rating in a research report on Thursday, December 13th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Wolfe Research began coverage on shares of Pfizer in a research report on Tuesday, October 23rd. They set a “market perform” rating for the company. Finally, BMO Capital Markets downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $47.00 to $46.00 in a research report on Thursday, November 1st. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and an average target price of $43.41.

NYSE:PFE opened at $42.53 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a 1-year low of $33.20 and a 1-year high of $46.47. The firm has a market capitalization of $258.00 billion, a P/E ratio of 16.05, a P/E/G ratio of 2.11 and a beta of 0.87.

Pfizer announced that its Board of Directors has initiated a stock buyback program on Friday, December 14th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 3.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, February 1st will be issued a $0.36 dividend. The ex-dividend date is Thursday, January 31st. This represents a $1.44 annualized dividend and a yield of 3.39%. This is a boost from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.

A number of hedge funds have recently modified their holdings of PFE. Advocacy Wealth Management Services LLC raised its position in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares during the period. Vestor Capital LLC bought a new stake in Pfizer in the 3rd quarter valued at $53,000. Arlington Partners LLC increased its holdings in Pfizer by 64.7% in the 4th quarter. Arlington Partners LLC now owns 2,141 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 841 shares during the last quarter. Fort L.P. bought a new stake in Pfizer in the 2nd quarter valued at $121,000. Finally, Highwater Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $123,000. Institutional investors own 69.26% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: What is the quiet period?

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.